CN112654348A - 含镇静药物的缓释药物组合物及其用途 - Google Patents

含镇静药物的缓释药物组合物及其用途 Download PDF

Info

Publication number
CN112654348A
CN112654348A CN201980057845.5A CN201980057845A CN112654348A CN 112654348 A CN112654348 A CN 112654348A CN 201980057845 A CN201980057845 A CN 201980057845A CN 112654348 A CN112654348 A CN 112654348A
Authority
CN
China
Prior art keywords
pharmaceutical composition
lipid
liposome
anesthetic
dexmedetomidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980057845.5A
Other languages
English (en)
Chinese (zh)
Inventor
洪基隆
沃尔特.高特尼
高颢文
林宜谕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiwan Liposome Co Ltd
TLC Biopharmaceuticals Inc
Original Assignee
Taiwan Liposome Co Ltd
TLC Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Co Ltd, TLC Biopharmaceuticals Inc filed Critical Taiwan Liposome Co Ltd
Publication of CN112654348A publication Critical patent/CN112654348A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980057845.5A 2018-09-13 2019-09-12 含镇静药物的缓释药物组合物及其用途 Pending CN112654348A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862730713P 2018-09-13 2018-09-13
US62/730,713 2018-09-13
PCT/US2019/050767 WO2020056102A1 (en) 2018-09-13 2019-09-12 Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof

Publications (1)

Publication Number Publication Date
CN112654348A true CN112654348A (zh) 2021-04-13

Family

ID=69777824

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980057845.5A Pending CN112654348A (zh) 2018-09-13 2019-09-12 含镇静药物的缓释药物组合物及其用途

Country Status (6)

Country Link
US (1) US20220054455A1 (enExample)
EP (1) EP3849532A4 (enExample)
JP (1) JP7482487B2 (enExample)
CN (1) CN112654348A (enExample)
TW (1) TWI755629B (enExample)
WO (1) WO2020056102A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116688137A (zh) * 2023-07-21 2023-09-05 中国医学科学院北京协和医院 一种基于核壳结构的药物组合物及应用
CN118986892A (zh) * 2024-09-29 2024-11-22 济南大学 一种醋酸阿比特龙胆盐脂质体组合物及其制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472158B2 (en) * 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
WO2021211575A1 (en) * 2020-04-13 2021-10-21 The Regents Of The Univefisity Of California Compositions comprising propofol, ketamine, and non-opioid analgesic, and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101756902A (zh) * 2008-12-23 2010-06-30 上海医药工业研究院 一种可乐定多囊脂质体及其制备方法
US20140220110A1 (en) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into liposomes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9700850A (es) * 1995-06-09 1997-09-30 Euro Celtique Sa Formulaciones y metodos para proporcionar anestesia local prolongada.
IL140892A0 (en) * 1998-08-12 2002-02-10 Yissum Res Dev Co Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
WO2006027787A1 (en) * 2004-09-09 2006-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal compositions of glucocorticoid and glucocorticoid derivatives
BR112013016365A2 (pt) * 2010-12-27 2018-06-26 Terumo Corp composição de lipossoma e processo para produção do mesmo
US20130096170A1 (en) * 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
AU2013256008B2 (en) * 2012-05-04 2016-02-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
EP2968145A1 (en) * 2013-03-13 2016-01-20 Mallinckrodt LLC Modified docetaxel liposome formulations
ES2777223T3 (es) * 2013-03-15 2020-08-04 Taiwan Liposome Co Ltd Composición de liposoma para liberación controlada de fármaco
US9895313B2 (en) * 2015-03-03 2018-02-20 Cureport, Inc. Combination liposomal pharmaceutical formulations
WO2016191547A1 (en) * 2015-05-26 2016-12-01 Comfort Care For Animals Llc Liposome loading
US11344498B2 (en) * 2015-10-08 2022-05-31 The Children's Medical Center Corporation Compositions and methods for on-demand high-efficiency triggerable anesthesia
MX2018008507A (es) * 2016-01-11 2019-07-04 Merrimack Pharmaceuticals Inc Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr).
EP3829539A4 (en) * 2018-08-02 2022-05-04 Taiwan Liposome Company, Ltd. DELAYED RELEASE COMPOSITIONS WITH A THERAPEUTIC AGENT FOR THE TREATMENT OF DEPRESSION OR ANXIETY AND USES THEREOF
US12285524B2 (en) * 2018-08-08 2025-04-29 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101756902A (zh) * 2008-12-23 2010-06-30 上海医药工业研究院 一种可乐定多囊脂质体及其制备方法
US20140220110A1 (en) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into liposomes

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116688137A (zh) * 2023-07-21 2023-09-05 中国医学科学院北京协和医院 一种基于核壳结构的药物组合物及应用
CN116688137B (zh) * 2023-07-21 2024-05-14 中国医学科学院北京协和医院 一种基于核壳结构的药物组合物及应用
CN118986892A (zh) * 2024-09-29 2024-11-22 济南大学 一种醋酸阿比特龙胆盐脂质体组合物及其制备方法

Also Published As

Publication number Publication date
TW202023618A (zh) 2020-07-01
WO2020056102A1 (en) 2020-03-19
TWI755629B (zh) 2022-02-21
EP3849532A1 (en) 2021-07-21
JP2022500398A (ja) 2022-01-04
JP7482487B2 (ja) 2024-05-14
EP3849532A4 (en) 2022-06-08
US20220054455A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
TWI776076B (zh) 含有治療失智症之治療劑的緩釋藥物組合物及其用途
TWI755629B (zh) 含鎮靜藥物之緩釋藥物組合物及其用途
TWI767133B (zh) 含有治療憂鬱症或焦慮症之治療劑的緩釋組合物及其用途
Hosny et al. Avanafil Liposomes as Transdermal Drug Delivery for Erectile Dysfunction Treatment: Preparation, Characterization, and In vitro, Ex vivo and In vivo Studies.
TWI772664B (zh) 含有抗精神病藥物的緩釋藥物組合物及其用途
HK40046574A (en) Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof
TWI767149B (zh) 含有免疫調節劑的緩釋藥物組合物及其用途
HK40054350A (zh) 含有免疫調節劑的緩釋藥物組合物及其用途
HK40043627A (en) Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof
HK40046579A (en) Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof
HK40045697A (en) Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof
HK40046579B (en) Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof
EP3880176A1 (en) Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating diseases due to reduced bone density or cartilage loss and uses thereof
HK40054349A (en) Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating diseases due to reduced bone density or cartilage loss and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40046574

Country of ref document: HK